Therapeutic Options for Recurrence of Primary Focal Segmental Glomerulonephritis (FSGS) in the Renal Allograft: Single-Center Experience
Abstract
:1. Introduction
2. Materials and Methods
Statistical Analysis
3. Results
3.1. Patient Characteristics
3.2. Treatment Options and Efficacy
3.3. Outcomes
4. Discussion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Schena, F.P. Epidemiology of end-stage renal disease: International comparisons of renal replacement therapy. Kidney Int. 2000, 57, S39–S45. [Google Scholar] [CrossRef] [Green Version]
- Golgert, W.A.; Appel, G.B.; Hariharan, S. Recurrent Glomerulonephritis after Renal Transplantation: An Unsolved Problem. Clin. J. Am. Soc. Nephrol. 2008, 3, 800–807. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hickson, L.J.; Gera, M.; Amer, H.; Iqbal, C.W.; Moore, T.B.; Milliner, D.S.; Cosio, F.G.; Larson, T.S.; Stegall, M.D.; Ishitani, M.B.; et al. Kidney Transplantation for Primary Focal Segmental Glomerulosclerosis: Outcomes and Response to Therapy for Recurrence. Transplantation 2009, 87, 1232–1239. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Uffing, A.; Pérez-Sáez, M.J.; Mazzali, M.; Manfro, R.C.; Bauer, A.C.; de SottomaiorDrumond, F.; O’shaughnessy, M.M.; Cheng, X.S.; Chin, K.K.; Ventura, C.G.; et al. Recurrence of FSGS after Kidney Transplantation in Adults. Clin. J. Am. Soc. Nephrol. 2020, 15, 247. [Google Scholar] [CrossRef]
- Maas, R.J.H.; Deegens, J.K.J.; van den Brand, J.A.J.G.; Cornelissen, E.A.M.; Wetzels, J.F.M. A retrospective study of focal segmental glomerulosclerosis: Clinical criteria can identify patients at high risk for recurrent disease after first renal transplantation. BMC Nephrol. 2013, 14, 47. [Google Scholar] [CrossRef] [Green Version]
- Koh, L.J.; Martz, K.; Blydt-Hansen, T.D.; the NAPRTCS Registry Investigators. Risk factors associated with allograft failure in pediatric kidney transplant recipients with focal segmental glomerulosclerosis. Pediatr. Transplant. 2019, 23, e13469. [Google Scholar] [CrossRef]
- Abbott, K.C.; Sawyers, E.S.; Oliver, J.D., III; Ko, C.W.; Kirk, A.D.; Welch, P.G.; Peters, T.G.; Agodoa, L.Y. Graft Loss Due to Recurrent Focal Segmental Glomerulosclerosis in Renal Transplant Recipients in the United States. Am. J. Kidney Dis. 2001, 37, 366–373. [Google Scholar] [CrossRef]
- Allen, P.J.; Chadban, S.J.; Craig, J.C.; Lim, W.H.; Allen, R.D.; Clayton, P.A.; Teixeira-Pinto, A.; Wong, G. Recurrent glomerulonephritis after kidney transplantation: Risk factors and allograft outcomes. Kidney Int. 2017, 92, 461–469. [Google Scholar] [CrossRef]
- Moroni, G.; Gallelli, B.; Quaglini, S.; Banfi, G.; Montagnino, G.; Messa, P. Long-term outcome of renal transplantation in adults with focal segmental glomerulosclerosis. Transpl. Int. 2010, 23, 208–216. [Google Scholar] [CrossRef] [Green Version]
- Cormican, S.; Kennedy, C.; O’Kelly, P.; Doyle, B.; Dorman, A.; Awan, A.; Conlon, P. Renal transplant outcomes in primary FSGS compared with other recipients and risk factors for recurrence: A national review of the Irish Transplant Registry. Clin. Transplant. 2018, 32, e13152. [Google Scholar] [CrossRef]
- Fuentes, G.M.; Meseguer, C.G.; Carrion, A.P.; Hijosa, M.M.; Garcia-Pose, A.; Melgar, A.A.; Torres, M.N. Long-term outcome of focal segmental glomerulosclerosis after pediatric renal transplantation. Pediatr. Nephrol. 2010, 25, 529–534. [Google Scholar] [CrossRef] [PubMed]
- Hariharan, S.; Adams, M.B.; Brennan, D.C.; Davis, C.L.; First, M.R.; Johnson, C.P.; Ouseph, R.; Peddi, V.R.; Pelz, C.J.; Roza, A.M.; et al. Recurrent and de novo Glomerular Disease after Renal Transplantation: A Report from Renal Allograft Disease Registry (RADR)1,2. Transplantation 1999, 68, 635–641. [Google Scholar] [CrossRef] [PubMed]
- Wei, C.; Trachtman, H.; Li, J.; Dong, C.; Friedman, A.L.; Gassman, J.J.; Mcmahan, J.L.; Radeva, M.; Heil, K.M.; Trautmann, A.; et al. Circulating suPAR in Two Cohorts of Primary FSGS. J. Am. Soc. Nephrol. 2012, 23, 2051–2059. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wei, C.; El Hindi, S.; Li, J.; Fornoni, A.; Goes, N.; Sageshima, J.; Maiguel, D.; Karumanchi, S.A.; Yap, H.-K.; Saleem, M.; et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat. Med. 2011, 17, 952–960. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Harel, E.; Shoji, J.; Abraham, V.; Miller, L.; Laszik, Z.G.; King, A.; Dobi, D.; Szabo, G.; Hann, B.; Sarwal, M.M.; et al. Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes. Transplantation 2020, 104, 54–60. [Google Scholar] [CrossRef]
- Delville, M.; Sigdel, T.K.; Wei, C.; Li, J.; Hsieh, S.C.; Fornoni, A.; Burke, G.W.; Bruneval, P.; Naesens, M.; Jackson, A.; et al. A circulating antibody panel for pretransplant prediction of FSGS recurrence after kidney transplantation. Sci. Transl. Med. 2014, 6, 256. [Google Scholar] [CrossRef] [Green Version]
- Ponticelli, C. Recurrence of focal segmental glomerular sclerosis (FSGS) after renal transplantation. Nephrol. Dial. Transplant. 2009, 25, 25–31. [Google Scholar] [CrossRef] [Green Version]
- Kashgary, A.; Sontrop, J.M.; Li, L.; Al-Jaishi, A.A.; Habibullah, Z.N.; Alsolaimani, R.; Clark, W.F. The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: A systematic review and meta-analysis of 77 case-reports and case-series. BMC Nephrol. 2016, 17, 104. [Google Scholar] [CrossRef] [Green Version]
- Ohta, T.; Kawaguchi, H.; Hattori, M.; Komatsu, Y.; Akioka, Y.; Nagata, M.; Shiraga, H.; Ito, K.; Takahashi, K.; Ishikawa, N.; et al. Effect of Pre- and Postoperative Plasmapheresis on Posttransplant Recurrence of Focal Segmental Glomerulosclerosis in Children. Transplantation 2001, 71, 628–633. [Google Scholar] [CrossRef]
- Gohh, R.Y.; Yango, A.F.; Morrissey, P.E.; Monaco, A.P.; Gautam, A.; Sharma, M.; McCarthy, E.T.; Savin, V.J. Preemptive Plasmapheresis and Recurrence of FSGS in High-Risk Renal Transplant Recipients. Arab. Archaeol. Epigr. 2005, 5, 2907–2912. [Google Scholar] [CrossRef] [PubMed]
- Valdivia, P.; Roncero, F.G.; Gentil, M.; Jimenez, F.; Algarra, G.; Pereira, P.; Rivera, M.; Suñer, M.; Cabello, V.; Toro, J.; et al. Plasmapheresis for the Prophylaxis and Treatment of Recurrent Focal Segmental Glomerulosclerosis Following Renal Transplant. Transplant. Proc. 2005, 37, 1473–1474. [Google Scholar] [CrossRef] [PubMed]
- Park, H.S.; Hong, Y.; Sun, I.O.; Chung, B.H.; Kim, H.W.; Choi, B.S.; Park, C.W.; Jin, D.C.; Kim, Y.S.; Yang, C.W. Effects of pretransplant plasmapheresis and rituximab on recurrence of focal segmental glomerulosclerosis in adult renal transplant recipients. Korean J. Intern. Med. 2014, 29, 482–488. [Google Scholar] [CrossRef] [PubMed]
- Messina, M.; Gallo, E.; Mella, A.; Pagani, F.; Biancone, L. Update on the treatment of focal segmental glomerulosclerosis in renal transplantation. World J. Transplant. 2016, 6, 54–68. [Google Scholar] [CrossRef] [PubMed]
- Kienzl-Wagner, K.; Waldegger, S.; Schneeberger, S. Disease Recurrence—The Sword of Damocles in Kidney Transplantation for Primary Focal Segmental Glomerulosclerosis. Front. Immunol. 2019, 10, 1669. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Alhamad, T.; Dieck, J.M.; Younus, U.; Matar, D.; Alasfar, S.; Vujjini, V.; Wall, D.; Kanawati, B.; Reiser, J.; Brennan, D.C.; et al. ACTH Gel in Resistant Focal Segmental Glomerulosclerosis After Kidney Transplantation. Transplantation 2019, 103, 202–209. [Google Scholar] [CrossRef] [PubMed]
- Grafals, M.; Sharfuddin, A. Adrenocorticotropic Hormone in the Treatment of Focal Segmental Glomerulosclerosis Following Kidney Transplantation. Transplant. Proc. 2019, 51, 1831–1837. [Google Scholar] [CrossRef] [PubMed]
- Canaud, G.; Zuber, J.; Sberro, R.; Royale, V.; Anglicheau, D.; Snanoudj, R.; Gaha, K.; Thervet, E.; Lefrère, F.; Cavazzana-Calvo, M.; et al. Intensive and Prolonged Treatment of Focal and Segmental Glomerulosclerosis Recurrence in Adult Kidney Transplant Recipients: A Pilot Study. Arab. Archaeol. Epigr. 2009, 9, 1081–1086. [Google Scholar] [CrossRef]
- Yu, C.C.; Fornoni, A.; Weins, A.; Hakroush, S.; Maiguel, D.; Sageshima, J.; Chen, L.; Ciancio, G.; Faridi, M.H.; Behr, D.; et al. Abatacept in B7-1-positive proteinuric kidney disease. N. Engl. J. Med. 2013, 369, 2416–2423. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Delville, M.; Baye, E.; Durrbach, A.; Audard, V.; Kofman, T.; Braun, L.; Olagne, J.; Nguyen, C.; Deschênes, G.; Moulin, B.; et al. B7–1 Blockade Does Not Improve Post–Transplant Nephrotic Syndrome Caused by Recurrent FSGS. J. Am. Soc. Nephrol. 2015, 27, 2520–2527. [Google Scholar] [CrossRef] [Green Version]
- Staeck, O.; Halleck, F.; Budde, K.; Khadzhynov, D. Long-Term Outcomes of Kidney Transplant Recipients with Primary Idiopathic Focal Segmental Glomerulosclerosis. Transplant. Proc. 2017, 49, 2256–2259. [Google Scholar] [CrossRef]
- Francis, A.; Trnka, P.; McTaggart, S.J. Long-Term Outcome of Kidney Transplantation in Recipients with Focal Segmental Glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2016, 11, 2041–2046. [Google Scholar] [CrossRef] [PubMed]
- GastònEZilleruelo, H.H. Recurrent focal glomerulosclerosis in pediatric renal allografts: The Miami experience. Pediatric Nephrol. 2004, 20, 210–216. [Google Scholar]
- Neff, R.T.; Jindal, R.M.; Yoo, D.Y.; Hurst, F.P.; Agodoa, L.Y.; Abbott, K.C. Analysis of USRDS: Incidence and Risk Factors for Pneumocystis jiroveci Pneumonia. Transplantation 2009, 88, 135–141. [Google Scholar] [CrossRef] [PubMed]
- Bouts, A.; Veltkamp, F.; Tönshoff, B.; Vivarelli, M. European Society of Pediatric Nephrology survey on current practice regarding recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation. Pediatr. Transplant. 2019, 23, e13385. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Odorico, J.S.; Knechtle, S.J.; Rayhill, S.C.; Pirsch, J.D.; D’Alessandro, A.M.; Belzer, F.O.; Sollinger, H.W. The Influence of Native Nephrectomy on The Incidence of Recurrent Disease Following Renal Transplantation for Primary Glomerulonephritis1. Transplantation 1996, 61, 228–234. [Google Scholar] [CrossRef] [PubMed]
- Baum, M.A. Outcomes after renal transplantation for FSGS in children. Pediatr. Transplant. 2004, 8, 329–333. [Google Scholar] [CrossRef] [PubMed]
- Araya, C.E.; Dharnidharka, V.R. The factors that may predict response to rituximab therapy in recurrent focal segmental glomerulosclerosis: A systematic review. J. Transplant. 2011, 2011, 374213. [Google Scholar] [CrossRef] [Green Version]
- Sakai, K.; Takasu, J.; Nihei, H.; Yonekura, T.; Aoki, Y.; Kawamura, T.; Mizuiri, S.; Aikawa, A. Protocol biopsies for focal segmental glomerulosclerosis treated with plasma exchange and rituximab in a renal transplant patient. Clin. Transplant. 2010, 24, 60–65. [Google Scholar] [CrossRef]
- Garrouste, C.; Canaud, G.; Büchler, M.; Rivalan, J.; Colosio, C.; Martinez, F.; Aniort, J.; Dudreuilh, C.; Pereira, B.; Caillard, S.; et al. Rituximab for Recurrence of Primary Focal Segmental Glomerulosclerosis After Kidney Transplantation: Clinical Outcomes. Transplantation 2017, 101, 649–656. [Google Scholar] [CrossRef]
- Lionaki, S.; Vlachopanos, G.; Georgalis, A.; Liapis, G.; Skalioti, C.; Zavos, G.; Boletis, J.N. Individualized scheme of immunoadsorption for the recurrence of idiopathic focal segmental glomerulosclerosis in the graft: A single center experience. Ren. Fail. 2015, 37, 1–7. [Google Scholar] [CrossRef]
- Zimmerman, S.W. Plasmapheresis and dipyridamole for recurrent focal glomerular sclerosis. Nephron 1985, 40, 241–245. [Google Scholar] [CrossRef] [PubMed]
- Bennani, H.N.; Bonzi, J.Y.; Noble, J.; Terrec, F.; Motte, L.; Imerzoukene, F.; Bugnazet, M.; Giovannini, D.; Janbon, B.; Malvezzi, P.; et al. Immunoadsorption for Recurrent Primary Focal Segmental Glomerulosclerosis on Kidney Allografts: A Single-Center Experience and Literature Review. Blood Purif. 2020, 49, 322–333. Available online: https://www.karger.com/DOI/10.1159/000504244 (accessed on 7 January 2020).
- Fogo, A.B. Causes and pathogenesis of focal segmental glomerulosclerosis. Nat. Rev. Nephrol. 2015, 11, 76–87. [Google Scholar] [CrossRef] [PubMed]
- Fornoni, A.; Sageshima, J.; Wei, C.; Merscher-Gomez, S.; Aguillon-Prada, R.; Jauregui, A.N.; Li, J.; Mattiazzi, A.; Ciancio, G.; Chen, L.; et al. Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis. Sci. Transl. Med. 2011, 3, 85ra46. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Manabe, S.; Nitta, K.; Nagata, M. Direct Effects of Immunomodulatory Agents on Podocytes in Immune-Mediated Glomerular Diseases. Contrib. Nephrol. 2018, 195, 131–142. [Google Scholar]
- Grellier, J.; Del Bello, A.; Milongo, D.; Guilbeau-Frugier, C.; Rostaing, L.; Kamar, N. Belatacept in recurrent focal segmental glomerulosclerosis after kidney transplantation. Transpl. Int. 2015, 28, 1109–1110. [Google Scholar] [CrossRef] [PubMed]
- Kristensen, T.; Ivarsen, P.; Povlsen, J.V. Unsuccessful Treatment with Abatacept in Recurrent Focal Segmental Glomerulosclerosis after Kidney Transplantation. Case Rep. Nephrol. Dial. 2017, 7, 1–5. [Google Scholar] [CrossRef] [Green Version]
- Chakraborty, R.; Mehta, A.; Nair, N.; Nemer, L.; Jain, R.; Joshi, H.; Raina, R. ACTH Treatment for Management of Nephrotic Syndrome: A Systematic Review and Reappraisal. Int. J. Nephrol. 2020, 2020, 1–16. [Google Scholar] [CrossRef]
- Gong, R. Leveraging melanocortin pathways to treat glomerular diseases. Adv. Chronic Kidney Dis. 2014, 21, 134–151. [Google Scholar] [CrossRef] [Green Version]
- Qiao, Y.; Berg, A.L.; Wang, P.; Ge, Y.; Quan, S.; Zhou, S.; Wang, H.; Liu, Z.; Gong, R. MC1R is dispensable for the proteinuria reducing and glomerular protective effect of melanocortin therapy. Sci. Rep. 2016, 6, 27589. [Google Scholar] [CrossRef]
- Elvin, J.; Buvall, L.; LindskogJonsson, A.; Granqvist, A.; Lassén, E.; Bergwall, L.; Nyström, J.; Haraldsson, B. Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation. Am. J. Physiol.-Ren. Physiol. 2016, 310, F846–F856. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bernard, J.; Bruel, A.; Allain-Launay, E.; Dantal, J.; Roussey-Kesler, G. Ofatumumab in post-transplantation recurrence of a pediatric steroid-resistant idiopathic nephrotic syndrome. Pediatr. Transplant. 2018, 22, e13175. [Google Scholar] [CrossRef] [PubMed]
- Colucci, M.; Labbadia, R.; Vivarelli, M.; Camassei, F.D.; Emma, F.; Strologo, L.D. Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis. Pediatr. Nephrol. 2019, 35, 341–345. [Google Scholar] [CrossRef] [PubMed]
- Solomon, S.; Zolotnitskaya, A.; Del Rio, M. Ofatumumab in post-transplantation recurrence of focal segmental glomerulosclerosis in a child. Pediatr. Transplant. 2019, 23, e13413. [Google Scholar] [CrossRef]
Recurrence | No Recurrence | p Value | |
---|---|---|---|
N | 26 (57) | 20 (43) | |
Gender (male) | 16 (67) | 13 (65) | 0.809 |
Age at transplantation (years) | 33.8 (±13) | 41.4 (±14.3) | 0.067 |
Age at onset (years) | 21.8 (±13) | 27.7 (±14.3) | 0.157 |
Time from diagnosis to ESRD (months) | 61.4 (15.4–110.7) | 111.2 (51–168.4) | 0.038 |
Time on RRT (months) | 30.3 (12–69.8) | 27.2 (13.1–74.5) | 0.622 |
Donor age (years) | 53 (±11.6) | 54.8 (±13.6) | 0.654 |
Donor (living/deceased) | 12/14 (46/54) | 13/7 (65/35) | 0.203 |
HLA mismatches | 2.5 (±1.2) | 2.6 (±1.3) | 0.941 |
Delayed graft function | 10 (39) | 3 (15) | 0.079 |
Number of transplantations | |||
1st | 23 (89) | 20 (100) | 0.110 |
2nd | 2 (8) | 0 | 0.204 |
3rd | 1 (4) | 0 | 0.375 |
Prophylactic plasmapheresis | 16 (62) | 18 (90) | 0.029 |
eGFR at year 1(mL/min/1.73 m2) | 45 (±18) | 53 (±15) | 0.104 |
Follow-up time (months) | 33.5 (23–57.8) | 33 (18.2–140.6) | 0.580 |
Graft loss due to any cause | 15 (58) | 0 (0) | |
Time to ESRD (months) | 31.5 (15.4–73.1) | NA |
Complete Remission | Partial Remission | No Remission | p Value | |
---|---|---|---|---|
N (%) | 7 (27) | 11 (42) | 8 (31) | |
Early/late recurrence | 6/2 (86/29) * | 11/3 (79/21) * | 6/2 (80/20) | |
Time to recurrence (months) | ||||
Early | 0.72 (±0.41) | 0.56 (±0.36) | 0.36 (±0.18) | 0.24 |
Late | 13.5 (±6.36) | 16.6 (±8.3) | 16 (±5.66) | 0.677 |
Maximal proteinuria (g/24 h) | 6.1 (3.71–9.15) | 9.5 (5.9–16.52) | 10.3 (5.8–12.37) | 0.434 |
Prophylactic plasmapheresis | 5 (71.4) | 7 (63.6) | 4 (50) | 0.684 |
Therapeutic plasmapheresis | 7 (100) | 11(100) | 8 (100) | |
Number of plasmaphereses | 16 (14–19) | 49 (24–61) | 14 (12–31) | 0.546 |
Rituximab | 2 (18.6) | 5 (45.5) | 1 (12.5) | 0.304 |
Abatacept | 0 | 0 | 1 (12.5) | 0.31 |
ACTH | 1 (14.3) | 2 (18.1) | 1 (12.5) | 0.94 |
Time to remission (months) | 3 (±1.79) | 4.4 (±2.25) | NA | 0.547 |
Graft loss due to FSGS | 0 | 4 (36.3) | 7 (87.5) | 0.025 |
Time to ESRD due to FSGS (months) | NA | 36.9 (29.74–44.82) | 18.3 (13.1–25.3) | 0.389 |
Graft loss due to any cause | 2 (25) | 6 (54.5) | 7 (87.5) | 0.122 |
Time to ESRD | 88.2 (52.15–124.38) | 33.1 (17.87–57.73) | 18.3 (13.1–25.3) | 0.745 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Vallianou, K.; Marinaki, S.; Skalioti, C.; Lionaki, S.; Darema, M.; Melexopoulou, C.; Boletis, I. Therapeutic Options for Recurrence of Primary Focal Segmental Glomerulonephritis (FSGS) in the Renal Allograft: Single-Center Experience. J. Clin. Med. 2021, 10, 373. https://doi.org/10.3390/jcm10030373
Vallianou K, Marinaki S, Skalioti C, Lionaki S, Darema M, Melexopoulou C, Boletis I. Therapeutic Options for Recurrence of Primary Focal Segmental Glomerulonephritis (FSGS) in the Renal Allograft: Single-Center Experience. Journal of Clinical Medicine. 2021; 10(3):373. https://doi.org/10.3390/jcm10030373
Chicago/Turabian StyleVallianou, Kalliopi, Smaragdi Marinaki, Chrysanthi Skalioti, Sophia Lionaki, Maria Darema, Christina Melexopoulou, and Ioannis Boletis. 2021. "Therapeutic Options for Recurrence of Primary Focal Segmental Glomerulonephritis (FSGS) in the Renal Allograft: Single-Center Experience" Journal of Clinical Medicine 10, no. 3: 373. https://doi.org/10.3390/jcm10030373